Go to deals
Healthcare

Igyxos S.A. has completed a Series A fundraising

Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.

Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.

Oaklins’ team in France advised Igyxos in a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Jean-Paul  Ortelli

Jean-Paul Ortelli

Senior Advisor

Paris, France
Oaklins France
 Leïla  Djebli

Leïla Djebli

Associate Director

Paris, France
Oaklins France

Related deals

Bango plc growth capital for expansion
Financial Services | TMT

Bango plc growth capital for expansion

Bango plc has raised capital to finance its expansion plans.

Learn more
Narva clinics has been acquired by Narva Åderbråckscenter AB
Healthcare

Narva clinics has been acquired by Narva Åderbråckscenter AB

The founder and some key employees of Åderbråcksspecialisterna Narva Kirurg Center AB and Narva Derma Center AB (Narva) have completed an MBO.

Learn more
Bright Network has completed a fundraising
Business Support Services | TMT

Bright Network has completed a fundraising

Bright Network has completed a fundraising to help support its continued growth.

Learn more